{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:12:21Z","timestamp":1790269941618,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008713","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T00:00:00Z","timestamp":1323216000000}}],"reference-count":65,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008713.pub2","type":"journal-article","created":{"date-parts":[[2011,12,5]],"date-time":"2011-12-05T16:44:27Z","timestamp":1323103467000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma"],"prefix":"10.1002","volume":"2011","author":[{"given":"Jian Hong","family":"Zhong","sequence":"first","affiliation":[{"name":"Tumor Hospital, Guangxi Medical University; Department of Hepato-Biliary Diseases; 71 Hei Di Road Nanning Guangxi China 530021"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Qun","family":"Li","sequence":"additional","affiliation":[{"name":"Tumor Hospital, Guangxi Medical University; Department of Hepato-Biliary Diseases; 71 Hei Di Road Nanning Guangxi China 530021"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu Cheng","family":"Wu","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital, Guangxi Medical University; Colorectal and Anal Department; 22 Shuangyong Road Nanning Guangxi China 530021"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,7]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD008713.pub2-BIB0001|cit1","first-page":"114","article-title":"Anti-viral therapy using lamivudine and thymosin is helpful to prevent recurrence in hepatocellular carcinoma with coexisting active hepatitis B","volume":"27","author":"Cheng","year":"2005","journal-title":"Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]"},{"issue":"68","key":"10.1002\/14651858.CD008713.pub2-BIB0002|cit2","first-page":"249","article-title":"Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection","volume":"53","author":"Cheng","year":"2006","journal-title":"Hepato-Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD008713.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00535-009-0093-z","article-title":"The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma","volume":"44","author":"Chuma","year":"2009","journal-title":"Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008713.pub2-BIB0004|cit4","first-page":"140","article-title":"The influence of hepatitis B viral load and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma","volume":"3","author":"Chuma","year":"2009","journal-title":"Hepatology International"},{"issue":"7","key":"10.1002\/14651858.CD008713.pub2-BIB0005|cit5","first-page":"752","article-title":"Influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma","volume":"40","author":"Chuma","year":"2010","journal-title":"Hepatology Research"},{"issue":"7","key":"10.1002\/14651858.CD008713.pub2-BIB0006|cit6","first-page":"984","article-title":"Clinical observation on lamivudine for treatment of hepatitis B virus-related hepatocellular carcinoma","volume":"25","author":"Han","year":"2009","journal-title":"Modern Medicine & Health"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD008713.pub2-BIB0007|cit7","first-page":"594a","article-title":"Therapeutic role of preemptive lamivudine therapy for the prevention of hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing transarterial chemolipiodolization: a randomized controlled study","volume":"42","author":"Jang","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD008713.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.21024","article-title":"A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization","volume":"43","author":"Jang","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD008713.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1478-3231.2008.01828.x","article-title":"Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma","volume":"29","author":"Kim","year":"2009","journal-title":"Liver International"},{"issue":"1","key":"10.1002\/14651858.CD008713.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2169\/internalmedicine.48.1534","article-title":"Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function","volume":"48","author":"Koda","year":"2009","journal-title":"Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008713.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1872-034X.2007.00013.x","article-title":"Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus","volume":"37","author":"Kubo","year":"2007","journal-title":"Hepatology Research"},{"issue":"11","key":"10.1002\/14651858.CD008713.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1440-1746.2006.04707.x","article-title":"Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma","volume":"22","author":"Kuzuya","year":"2007","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"15","key":"10.1002\/14651858.CD008713.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.11569\/wcjd.v16.i15.1700","article-title":"Lamivudine therapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma complicated by hepatitis B virus: An analysis of 30 cases","volume":"16","author":"Li","year":"2008","journal-title":"World Chinese Journal of Digestology"},{"issue":"1","key":"10.1002\/14651858.CD008713.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1245\/s10434-009-0694-z","article-title":"A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection","volume":"17","author":"Li","year":"2009","journal-title":"Annals of Surgical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD008713.pub2-BIB0015|cit15","first-page":"755","article-title":"Lamivudine therapy after percutaneous microwave coagulation therapy for patients with primary hepatocellular carcinoma complicated with hepatitis B virus: an analysis of 40 cases","volume":"18","author":"Peng","year":"2010","journal-title":"Journal of Modern Oncology"},{"issue":"5","key":"10.1002\/14651858.CD008713.pub2-BIB0016|cit16","first-page":"217","article-title":"Lamivudine treatment in patients with HBV-related hepatocellular carcinoma - using an untreated, matched control cohort","volume":"59","author":"Piao","year":"2005","journal-title":"Acta Medica Okayama"},{"issue":"2","key":"10.1002\/14651858.CD008713.pub2-BIB0017|cit17","first-page":"95","article-title":"Therapeutic efficacy of lamivudine in preventing the activity of hepatitis B virus in perioperative patients with hepatocellular carcinoma","volume":"21","author":"Wang","year":"2001","journal-title":"Chinese Journal of Practical Surgery"},{"issue":"6","key":"10.1002\/14651858.CD008713.pub2-BIB0018|cit18","first-page":"726","article-title":"A study of antiviral therapy in prevention of tumor recurrence after curative treatment of hepatocellular carcinoma","volume":"35","author":"Yang","year":"2010","journal-title":"Medical Journal of Chinese People's Liberation Army"},{"issue":"1","key":"10.1002\/14651858.CD008713.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12072-007-9020-7","article-title":"Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma","volume":"2","author":"Yoshida","year":"2008","journal-title":"Hepatology International"},{"issue":"9","key":"10.1002\/14651858.CD008713.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ejso.2005.04.002","article-title":"Liver resection for hepatocellular carcinoma on cirrhosis: analysis of mortality, morbidity and survival - a European single center experience","volume":"31","author":"Capussotti","year":"2005","journal-title":"European Journal of Surgical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD008713.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/hep.510270634","article-title":"Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy","volume":"27","author":"Chayama","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD008713.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD008713.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","article-title":"Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir","volume":"36","author":"Cundy","year":"1999","journal-title":"Clinical Pharmacokinetics"},{"issue":"3","key":"10.1002\/14651858.CD008713.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/jhep.2001.26815","article-title":"Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection","volume":"34","author":"Man","year":"2001","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD008713.pub2-BIB0025|cit25","first-page":"285\u2013312","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","volume-title":"Systematic Reviews in Health Care. Meta-Analysis in Context","author":"Deeks","year":"2001"},{"issue":"1","key":"10.1002\/14651858.CD008713.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/gast.2003.50013","article-title":"Histological outcome during long-term lamivudine therapy","volume":"124","author":"Dienstag","year":"2003","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD008713.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jamcollsurg.2005.06.265","article-title":"Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival","volume":"201","author":"Dupont-Bierre","year":"2005","journal-title":"Journal of the American College of Surgeons"},{"issue":"7109","key":"10.1002\/14651858.CD008713.pub2-BIB0028|cit28","first-page":"629","article-title":"Bias in meta analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD008713.pub2-BIB0029|cit29","unstructured":"Gluud C Nikolova D Klingenberg SL Alexakis N Als-Nielsen B Colli A Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2011, Issue 9. Art. No.: LIVER"},{"issue":"6","key":"10.1002\/14651858.CD008713.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"issue":"7414","key":"10.1002\/14651858.CD008713.pub2-BIB0031|cit31","first-page":"557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD008713.pub2-BIB0032|cit32","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008713.pub2-BIB0033|cit33","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"5","key":"10.1002\/14651858.CD008713.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2893.1998.00116.x","article-title":"Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma","volume":"5","author":"Idilman","year":"1998","journal-title":"Journal of Viral Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD008713.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008713.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","article-title":"Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy","volume":"38","author":"Imamura","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD008713.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008713.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1349-7006.1998.tb00580.x","article-title":"Clinicopathological criteria for multicentricity of hepatocellular carcinoma and risk factors for such carcinogenesis","volume":"89","author":"Kubo","year":"1998","journal-title":"Japanese Journal of Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD008713.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/17474124.2.4.465","article-title":"Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection","volume":"2","author":"Kumar","year":"2008","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD008713.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group","volume":"339","author":"Lai","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008713.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1479-666X(05)80043-5","article-title":"The continuing challenge of hepatic cancer in Asia","volume":"3","author":"Lai","year":"2005","journal-title":"Surgeon"},{"issue":"1","key":"10.1002\/14651858.CD008713.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jamcollsurg.2007.03.002","article-title":"Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers","volume":"205","author":"Lang","year":"2007","journal-title":"Journal of the American College of Surgeons"},{"issue":"26","key":"10.1002\/14651858.CD008713.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008713.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1245\/s10434-009-0694-z","article-title":"A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection","volume":"17","author":"Li","year":"2010","journal-title":"Annals of Surgical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD008713.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.510300221","article-title":"Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy","volume":"30","author":"Liaw","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD008713.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/gast.2000.8559","article-title":"Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group","volume":"119","author":"Liaw","year":"2000","journal-title":"Gastroenterology"},{"issue":"9399","key":"10.1002\/14651858.CD008713.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD008713.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/jhep.2000.19622","article-title":"Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy","volume":"32","author":"Lok","year":"2000","journal-title":"Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD008713.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"9128","key":"10.1002\/14651858.CD008713.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD008713.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0168-8278(00)80428-6","article-title":"Hepatocellular carcinoma","volume":"32","author":"Okuda","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD008713.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.amjmed.2006.11.020","article-title":"Hepatocellular cancer: a guide for the internist","volume":"120","author":"Parikh","year":"2007","journal-title":"American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008713.pub2-BIB0053|cit53","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"4","key":"10.1002\/14651858.CD008713.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD008713.pub2-BIB0055|cit55","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"4","key":"10.1002\/14651858.CD008713.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"5","key":"10.1002\/14651858.CD008713.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD008713.pub2-BIB0058|cit58","first-page":"401","article-title":"Recurrence after resection of hepatocellular carcinoma","volume":"1","author":"Shen","year":"2002","journal-title":"Hepatobiliary & Pancreatic Diseases International"},{"issue":"2","key":"10.1002\/14651858.CD008713.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2005-871194","article-title":"Hepatocellular carcinoma: epidemiology, risk factors, and screening","volume":"25","author":"Sherman","year":"2005","journal-title":"Seminars in Liver Disease"},{"issue":"3","key":"10.1002\/14651858.CD008713.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/jhep.2001.22166","article-title":"Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region","volume":"33","author":"Stuyver","year":"2001","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD008713.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/cncr.10391","article-title":"Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis","volume":"94","author":"Tarao","year":"2002","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD008713.pub2-BIB0062|cit62","unstructured":"World Health Organization Mortality database http:\/\/www.who.int\/healthinfo\/morttables\/en\/"},{"issue":"7644","key":"10.1002\/14651858.CD008713.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD008713.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2002.34740","article-title":"Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks","volume":"36","author":"Yang","year":"2002","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD008713.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1751-2980.2009.00375.x","article-title":"A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China","volume":"10","author":"Yao","year":"2009","journal-title":"Journal of Digestive Diseases"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008713.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:47:34Z","timestamp":1790268454000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008713.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,12,7]]},"references-count":65,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008713.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,7]]}}}